Neonatal Solid Tumors: Incidence and Survival in France.
Solid tumors are uncommon in the neonatal period but represent an important cause of mortality and morbidity.



Using the French National Registry of Childhood Solid Tumors database, all children, from birth to 28 days of age inclusive, with a primary malignant solid tumor diagnosed between 2000 and 2009 in mainland France were identified. Tumors were classified according to the third version of the International Classification of Childhood Cancer.



Of total 285 solid tumors over 10 years, the most common cancer was neuroblastoma (47%), followed by germ cell tumors (29%), central nervous system tumors (10%), and soft tissue sarcomas (8%). The annual incidence was 36.6 per million live births. No statistically significant change in time trends of incidence was observed during 2000-2009. Routine ultrasonography during pregnancy established the diagnosis in 52% of cases. Thirteen neonates (4.5%) had congenital abnormalities associated with their tumors. For all solid tumors combined, overall survival was 84.2% (95% CI, 79.4-87.9) at 1 year and 83.8% (95% CI, 79.0-87.6) at 5 years. More favorable prognosis was significantly associated with neonates treated by surgery (65% of cases) compared to those without tumor excision. However, perioperative and postoperative mortality was 8%.



Because of their relative rarity, there is a paucity of objective information on the epidemiology, optimal treatment, and long-term outcome of neonatal solid tumors. But to obtain a clearer picture of the epidemiology of neonatal tumors, it is essential to have some recommendations on the methodological approach used to study them.
CHU Nancy, Registre National des Cancers de l'Enfant, Registre National des Tumeurs Solides de l'Enfant, Faculté de médecine, Vandoeuvre-lès-Nancy F-54500, France.|Université Paris-Sorbonne, CRESS équipe 7, Inserm UMRS-1153, Paris, F-75006, France.
Emmanuel
E
Desandes
CHU Nancy, Registre National des Cancers de l'Enfant, Registre National des Tumeurs Solides de l'Enfant, Faculté de médecine, Vandoeuvre-lès-Nancy F-54500, France.
Sandra
S
Guissou
CHU Bordeaux, Service d'onco-hématologie pédiatrique, Bordeaux F-33000, France.
Stéphane
S
Ducassou
CHU Nancy, Registre National des Cancers de l'Enfant, Registre National des Tumeurs Solides de l'Enfant, Faculté de médecine, Vandoeuvre-lès-Nancy F-54500, France.|Université Paris-Sorbonne, CRESS équipe 7, Inserm UMRS-1153, Paris, F-75006, France.
Brigitte
B
Lacour
D016543:Central Nervous System Neoplasms / Q000453:epidemiology* / Q000401:mortality; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000453:epidemiology* / Q000401:mortality; D009447:Neuroblastoma / Q000453:epidemiology* / Q000401:mortality; D012042:Registries; D015996:Survival Rate
epidemiology; incidence; neonatal tumors; population-based study; survival